Mike Serrano-Wu joined the Broad Institute in 2012, and is the Director of Preclinical Discovery and Development for the Therapeutics Projects Group (TPG).
Serrano-Wu brings extensive knowledge of drug discovery and development to the Broad. Previously at Bristol-Myers Squibb, he was part of an industry-leading group that discovered the first-in-class HCV NS5A inhibitor daclatasvir, now in late-stage clinical testing and showing promise for highly effective interferon-free therapy. Later at Novartis Institutes for Biomedical Research, Inc., Serrano-Wu co-led a team that identified a first-in-class DGAT1 inhibitor currently in late-stage clinical testing and a second-generation compound that achieved successful Phase 1 proof of concept.
Serrano-Wu received his A.B. and Ph.D. in chemistry from Harvard University.Last updated date: May 2013